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Introduction 
Von Recklinghausen neurofibromatosis, or neurofi- 
bromatosis type 1 (NFI), affects approximately 1 in 
3500 individuals of all ethnic backgrounds. It is inher- 
ited as an autosomal dominant disease and is mani- 
fested clinically by abnormalities that predominantly 
affect tissues which derive from the neural crest (Ric- 
cardi, 1981,199l; Riccardi and Eichner, 1986). Affected 
individuals are often noted to have multiple cafe- 
au-lait spots during the first year of life. These pig- 
mented birthmarks contain melanocytes harboring 
macromelanosomes, but have noclinical significance 
other than as a diagnostic clue. Similarly, another im- 
portant clinical feature, the presence of Lisch nodules 
of the iris, has no associated morbidity. However, 
these hamartomas appear during childhood and are 
eventually present in close to 100% of affected adults. 
Neurofibromas, which give the disease its name and 
usually make their appearance just before or during 
adolescence, are benign cutaneous tumors consisting 
of Schwann cells, fibroblasts, and other cellular ele- 
ments. They increase in size and number with age, 
but at an unpredictable rate. More deeply placed neu- 
rofibromas, called plexiform lesions, usually appear 
in childhood and can lead to significant complications 
due to associated overgrowth of nearby tissues. Fur- 
thermore, such plexiform lesions have a modest but 
significant risk of degenerating into malignant neuro- 
fibrosarcoma, a highly invasive soft tissue tumor that 
is frequently fatal. This potential, plus the risk of optic 
glioma (which affects 2%-S% of all individuals with 
NFI) justifies placing this disease on the list of familial 
cancer syndromes (Bader, 1986). 
Other features of NFI arevariable but can be signifi- 
cant in a given patient. Approximately half of affected 
individuals have at least some degree of learning dis- 
ability, and a small percentage have frank mental re- 
tardation (Riccardi, 1981). Seizures are present in 
about 5% of individuals, and megalencephaly is a typi- 
cal finding. The diagnosis is usually not difficult to 
make in an adolescent or adult, but can occasionally 
present difficulties in a very young child. NFI is char- 
acterized by extreme variability, even among indi- 
viduals within the same family who carry the same 
mutation. 
Approximately two-thirds of individuals with NFI 
lead relatively normal lives, with occasional interrup- 
tions for surgical management of their disease, often 
to remove neurofibromas that are causing cosmetic 
or physical distress. About one-third of individuals 
suffer a severe complication sometime during their 
lifetime. NFI has occasionally been erroneously re- 
ferred to as “the elephant man disease”; while the 
gross facial distortion and other deformities present 
in Joseph Merrick, the Elephant Man, in some ways 
resemble the most severe end of the spectrum of NFI, 
subsequent evaluation of Merrick’s skeleton indicates 
that he probably had another disorder known as Pro- 
teus syndrome (Tibbles and Cohen, 1986). 
Cloning of the NFI Gene 
The gene for NFI was identified in 1990 by positional 
cloning, an approach that relies on isolating an un- 
known gene through knowledge of its chromosomal 
location (Figure 1) (Viskochil et al., 1990; Cawthon et 
al., 1990b; Wallace et al., 1990). The NF? gene spans 
over 300 kb of genomic DNA and encodes an mRNA 
of II-13 kb found in all t issues examined (Figure 2) 
(Wallace et al., 1990; Marchuk et al., 1991). This rather 
large gene contains approximately 50 exons and pro- 
duces a protein of 2818 amino acids with a predicted 
molecular mass of 327 kd (Marchuk et al., 1991). Of 
particular interest are three genes found buried 
within one intron on the DNA strand opposite the 
strand coding for the NF? gene (Viskochil et al., 1990). 
Two of these genes are human homologs of genes 
postulated to be activated by retroviral insertion in 
murine leukemia (EV12A and EV/2B), and the third 
gene (OMgP) encodes the oligodendrocyte myelin 
glycoprotein expressed in myelinating Schwann cells 
and oligodendrocytes (Cawthon et al., 1990a, 1990b; 
O ’Connell et al., 1990; Viskochil et al., 1991). The rela- 
tionship between these embedded genes and NFI re- 
mains to be elucidated. 
Based on the presence of multiple tumors in af- 
fected patients and the fact that the first few mutations 
in the NFI gene appeared to inactivate it, NFI was 
hypothesized to represent one member of the grow- 
ing family of tumor suppressor genes (Stanbridge, 
1990; Ponder, 1990). It was predicted, furthermore, 
that the NF? gene product might have an important 
role in modulating cell growth and differentiation in 
the nervous system. 
Identification of the NFI Gene Product 
Examination of the predicted protein sequenceof the 
NF7 gene product, termed neurofibromin, revealed 
sequence similarity between neurofibromin and vari- 
ous members of the GTPase-activating protein (GAP) 
superfamily (Figure 3) (Xu et al., 1990a, 1990b; Martin 
et al., 1990; Ballester et al., 1990). This family includes 
mammalian GAP, budding yeast IRA1 and IRA2, fis- 
sion yeast sarl, and Drosophila Capl. The first GAP 
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to be well characterized was mammalian pl20-GAP 
(Trahey and McCormick, 1987; Vogel et al., 1988). This 
protein is highly expressed in brain and placenta and 
is involved in growth factor-mediated signal trans- 
duction pathways. The two yeast genes, IRA? and 
IRA2, code for proteins that regulate RAS in Saccharo- 
myces cerevisiae and participate in the regulation of 
adenylate cyclase (Tanaka et al., 1989, 1990a, 1990b, 
1991). In contrast, the sari gene product from Schizo- 
saccharomyces pombe regulates Rasl but does not 
appear to participate in the modulation of adenylate 
cyclase (Wang et al., 1991). Recently the Drosophila 
homolog of GAP was identified and shown to be a 
negative regulator of Rasl (Gaul et al., 1992). Activa- 
tion of Rasl is critical for the orderly development of 
the fruitfly compound eye and represents part of a sig- 
nal transduction pathway involving receptor-mediated 
tyrosine phosphorylation (see below) (Pawson and 
Bernstein, 1990). The shared sequence similarity be- 
tweenthesediverseproteinslieswithina250400amino 
acid domain, termed the catalytic domain, which inter- 
acts with a cellular proto-oncogene, p21~~, accelerating 
its conversion from an active GTP-bound state to an 
inactive GDP-bound state (Figure 4) (Wigler, 1990). Acti- 
vation of ras has previously been shown to promote cell 
proliferation in some mammalian cells and differentia- 
tion in others (see below) (Bourne et al., 1990, 1991). 
The NH gene product has no transmembrane do- 
mains, definite nuclear localization signals, or other 
common protein motifs. It contains several potential 
sites for phosphorylation, raising the possibility that 
neurofibromin could be regulated by kinases (Mar- 
chuk et al., 1991). 
clustered within the originally defined 
broad chromosomal region are used to an- 
alyze families with the disease in order to 
narrow the interval to l-2 Mb (1 CM - 
1,000,000 nucleotides or 1 Mb), provided 
sufficient families are available. At this 
point, efforts are directed at cloning the 
entire region using the DNA markers most 
tightly associated with the disease, as de 
termined by linkage analysis. This can be 
accomplished by various technologies, in- 
cludingyeastartificialchromosomes,chro- 
mosomal jumping, and cosmid cloning. 
The DNA segments covering the interval 
are then used to screen cDNA libraries in 
an effort to identify potential transcripts for 
the disease gene. Proof that the gene iden- 
tified represents the desired disease gene 
requires the demonstration of mutations 
in that gene in patients with the disease 
flaken from Collins, 1992.) 
To understand the function of neurofibromin bet- 
ter, antibodies were generated by several groups 
against both fusion proteins and synthetic peptides 
(DeClue et al., 1991; Gutmann et al., 1991; Daston et 
al., 1992; Basu et al., 1992). These antibodies all recog- 
nize a protein with an M, of -250,000, expressed in 
all t issues but at highest levels in brain, kidney, and 
spleen. The broad expression of neurofibromin, in- 
cluding high levels in brain, was an unexpected find- 
ing given the disease phenotype. Although neurofi- 
bromin can be detected in crude homogenates from 
all tissues, careful quantification reveals that the ex- 
pression of neurofibromin in brain is greater than it 
is in spleen, adrenal gland, or kidney (Gutmann and 
Collins, unpublished data). The cells within the kid- 
ney that express neurofibromin remain to be eluci- 
dated. On the other hand, the expression of neurofi- 
bromin in spleen is the result of expression in both T 
and B lymphocytes(Cutmann and Collins, unpublished 
data). Neurofibromin expression in other tissues (lung, 
muscle, skin, or gonads) is barely detectable by immu- 
nohistochemical analysis. With sensitive polymerase 
chain reaction-based methods, however, NH mRNA 
appears to be ubiquitously expressed (Wallace et al., 
1990). 
Neurofibromin is expressed in many neuronal cell 
types, irrespective of neurotransmitter expression, 
neuronal pathway, or brain region. This protein in neu- 
rons appears to be most abundant in dendritic pro- 
cesses, where input messages would likely be trans- 
duced (Daston et al., 1992). This is in keeping with a 
protein that may be involved in signal transduction 
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Figure 2. Genetic Organization of the NF7 Locus 
The genomic architecture of the NH locus demonstrates the 
presence of two Not1 restriction sites (N) separated by -300 kb. 
The initiation codon is upstream of the centromeric Not1 site and 
is found within a CpC-rich area, as has been described for many 
genes. The position of the two translocation breakpoints, t(1;17) 
and t(17;22),found in two patientswith NFl isdepicted, and their 
interruption of the NF7 gene is evident. Threeembedded genes 
(OMgP, EV/2A, and EV12B) are located within one intron on the 
opposite strand and are transcribed in the opposite orientation 
from the NH gene. The mRNA for NF1 is 13 kb and contains an 
open reading frame of 8454 nucleotides with at least 2 kb of 3 
untranslated sequence. Translation of the open reading frame 
predicts a protein of 2818 amino acids and an estimated molecu- 
lar mass of 327 kd. Sequence similarity between a central 300- 
400 amino acid domain of the NF7 gene product, neurofibromin, 
and a family of CAPS is denoted by the CRD. The presence of 
two alternatively spliced isoforms is denoted by the 21 amino 
acid and 18 amino acid insertions into the GRD and the carboxyl 
terminus of neurofibromin, respectively. 
within the central nervous system that express neuro- 
fibromin include oligodendrocytes and cortical neu- 
rons. In the peripheral nervous system, this protein is 
expressed in nonmyelinating Schwann cells, dorsal 
root ganglia, and peripheral nerves (Daston et al., 
1992). 
The observed molecular size of neurofibromin 
(-250 kd) is smaller than would have been predicted 
based on translation of the NF? open reading frame 
(327 kd). This discrepancy is most likely the result of 
protein folding during migration through denaturing 
polyacrylamide gels.There is no evidence for glycosyl- 
ation or processing of the full-length protein (Gut- 
mann and Collins, unpublished data). There is one 
well-characterized alternatively spliced isoform of 
neurofibromin that has been termed type 2 neurofi- 
bromin (Nishi et al., 1991; Andersen et al., 1993a). This 
isoform contains an additional 21 amino acids in- 
serted within the GAP-related domain (GRD) and is 
expressed at the RNA level in all t issues examined. 
Type 2 NF7 mRNA is detectable in many species, in- 
cluding mouse, rat, and chicken. Expression of the 
type 2 NFI GRD in yeast complementation studies 
demonstrates that it has weaker GAP properties than 
the type 1 NFI GRD form. The relative abundance 
of the type 1 versus the type 2 form is modulated 
differentially during brain development and can be 
affected by stimulation with retinoic acid (Nishi et al., 
1991). The predominant mRNA at 20 weeks of human 
fetal development is type 1 NF? mRNA. A rapid switch 
begins before week 22, culminating in mainly type 2 
NF7 mRNA in the adult brain. The expression of 
type 1 versus type 2 NF7 mRNA has also been studied 
using neuroblastoma cell lines (Nishi et al., 1991). 
Stimulation of the neuroblastoma cell line, SH-SY5Y 
with retinoic acid (a treatment that promotes differen- 
tiation of SH-SY5Y cells to a more neuronal cell pheno- 
type) results in the rapid switch from type 1 NF7 mRNA 
to type 2 NF7 mRNA expression. This mRNA switch is 
not observed with an astrocytoma cell line similarly 
treated with retinoic acid. The significance of both 
of these findings at the protein level awaits further 
elucidation. 
Another isoform, generated by the insertion of an 
additional 18 amino acids near the extreme carboxyl 
terminus of the protein, has been reported at the 
mRNA level, but further work will be required to char- 
acterize this isoform (Cawthon et al., 199Ob).  
The availability of antibody reagents has allowed an 
examination of the subcellular localization of neurofi- 
bromin. It appears that neurofibromin is expressed 
predominantly in the cytoplasm and is in some way 
associated with the intracytoplasmic cytoskeleton. Re- 
cent experiments demonstrate the unexpected colo- 
calization of neurofibromin with cytoplasmic micro- 
tubules (Gregory et al., 1993; Gutmann et al., 1992, 
J. Cell Biochem., abstract). Further support for this 
subcellular localization is provided by biochemical 
copurification experiments during which brain neu- 
rofibromin is enriched in polymerized microtubule 
fractions. It is not clear at this time whether the type 2 
neurofibromin isoform also associates with microtu- 
bules. This location suggests that neurofibromin may 
be involved in signal transduction pathways associ- 
ated with microtubules and in that fashion, play some 
role in mediating cytoarchitectural alterations coinci- 
dent with neoplastic transformation. 
Mutational Basis of Disease 
Whereas the inherited predisposition to developing 
the clinical manifestations of NFI is transmitted in a 
Mendelian autosomal dominant fashion, it is hypothe- 
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neuroflbromln Figure 3. Sequence Similarity between 





The shaded areas represent the regions of 
sequence similarity between neurofibro- 
min and the catalytic GRDs of these other 
proteins. The size of each protein is de 
noted by the number of amino acid resi- 





sized that pathology arises only when both copies 
of the NF7 gene are disrupted (Knudson, 1971). The 
inherited predisposition represents the germline mu- 
tation, which disrupts one of the two normal copies 
of the NF7 gene and is found in all cells of NFI patients. 
To produce a neurofibroma or any other clinical fea- 
ture of NFI, a second mutational event must presum- 
ablyoccurtoeliminatetheremainingfunctionalgene. 
This second “hit” represents the somatic mutation. 
Thus, although NFI is an autosomal dominant disor- 
der in families, it is recessive at the cellular level. This 
is a unifying feature of diseases attributable to tumor 
suppressor gene abnormalities. 
Tumor formation arises as a result of alterations in 
genes that regulate cell proliferation. In normal cells, 
there are many such genes whose products control 
cell growth and whose absence, due to mutation, re- 
sults in a state of uncontrolled cell proliferation or 
neoplasia (Marshall, 1991). These genes are collec- 
tively referred to as tumor suppressor genes. The fact 
that there are many such genes provides support for 
the notion that tumorigenesis represents a multistep 
process: Loss of one tumor suppressor gene product 
may enlarge a population of cells with mildly altered 
cell growth potential and create a substrate for subse- 
quent tumor suppressor gene mutations, culminating 
in neoplasia. 
The best example of an inherited predisposition to 
cancer has come from the study of retinoblastoma, 
the most common intraocular malignancy in children. 
Retinoblastoma can occur sporadically or as a herita- 
ble condition. The notion that there exists a primary 
inherited genetic alteration which predisposes to the 
development of retinoblastoma is supported by cyto- 
genetic analysis demonstrating a visible deletion in 
one area of chromosome 13 (band q14), representing 
the germline mutation (Cavanee et al., 1983). Analysis 
of matched pairs of constitutional and tumor geno- 
types in cases of retinoblastoma demonstrated an 
additional alteration in the tumor chromosome 13, 
representing the acquired somatic mutation and dis- 
rupting both retinpblastoma tumor suppressor genes 
(Cavanee et al., 1985). Osteosarcoma and premeno- 
pausal breast cancer are also associated with retino- 
blastoma, and similar alterations on chromosome 
13q14 were also found when these tumors from reti- 
noblastoma patients were analyzed (reviewed in Han- 
sen and Cavenee, 1988). 
To date, only a small number of germline mutations 
have been characterized in NFI patients. The large 
size of the gene has represented a considerable bar- 
rier to such investigations, and only a minority of pa- 
tients have had the sort of gross rearrangements that 
are easily detectable. No hot spots for mutation have 
been identified, and there is no readily discernable 
genotype-phenotype correlation. The latter is not 
really stirprising, since the very large degree of pheno- 
typic variability commonly observed among affected 
members of the same family would preclude the pos- 
sibility that severity is tightly defined by the specific 
Neurofibromin 
GDP GTP 
Figure 4. Regulation of Ras by GAP-Related Proteins 
Ras is active in the CTP-bound state. Association of GAP-related 
proteins with ras accelerates the conversion of p2W.GTP to 
p21faS.CDP by increasing the intrinsic GTPase activity of ras. Hy- 
drolysis of p21”.GTP converts ras to the inactive GDP-bound 
form. Ras is converted to the active state by guanosine nucleo- 
tide replacing proteins, which substitute CTP for GDP and com- 
plete the cycle. In resting cells, the majority of ras is in the inac- 
tive, GDP-bound form. 
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Table 1. Characterized Cermline NF7 Mutations in Patients with NFI 
Mutation 
Deletions 
40 kb deletion 
190 kb deletion 
11 kb deletion 
90 kb deletion 
10 Mb deletion 
Insertions 









Splice disruption, frameshift 
- 
Reference 
Viskochil et al., 1990 
Viskochil et al., 1990 
Viskochil et al., 1990 
Upadhyaya, 1992 
Kayes, 1992 
Wallace et al., 1991 
Fountain et al., 1989 
O’Connell, 1989 
1722 translocation - Fountain et al., 1989 
O’Connell 1989 
Point Mutations 
Lys-1423 to Glu 
Lys-1423 to Gln 
Arg-1610 to stop 
Nonconservative amino acid changes; 
reduced GAP activity 
Creation of stop codon 
Li et al., 1992 
Cawthon et al., 1990b 
Estivill et al., 1991 
Leu-1595 to Pro Conservative amino acid change; ? polymorphism Cawthon et al., 1990b 
NF? mutation. The majority of mutations described 
thus far have been alterations (nonsense mutations, 
deletions, frameshift mutations, and insertions) that 
would be predicted to result in no neurofibromin pro- 
duction from that allele (Table 1). One convincing mis- 
sense mutation within the GRD at residue 1423 has 
been identified in an NFI family (Li et al., 1992). The 
NFI GRD harboring this mutation, when expressed 
in insect Sf9 or bacterial cells, had 200- to 400-fold 
reduced GAP activity, suggesting that this mutation 
affects the normal function of neurofibromin. 
Examination of tumors from NFI patients is begin- 
ning to uncover somatic alterationsof NF? on the DNA 
and protein levels. Benign neurofibromas are difficult 
to examine for altered neurofibromin expression, 
since they harbor a mixed population of cells. Al- 
though they presumably contain some cellular ele- 
ment with a second hit, the expression of neurofi- 
bromin is presumably normal in the other unaffected 
cells. On  the other hand, neurofibrosarcomas, malig- 
nant schwannomas derived from neurofibromas, 
have been shown to be clonal and to express nearly 
undetectable levels of neurofibromin (Basu et al., 
1992; DeClue et al., 1992). In one NFI neurofibrosar- 
coma, a specific somatic 200 kb deletion eliminating 
the amino-terminal half of one NF? genewas detected 
(Legius et al., 1993). 
terminal half of the NF7 gene in one tumor (Ander- 
sen et al., 1993b). The codon 1423 mutation described 
above has also been found in a sporadic colon adeno- 
carcinoma, a patient with myelodysplastic syndrome, 
and a sporadic anaplastic astrocytoma (Li et al., 1992). 
These findings are consistent with the notion that neu- 
rofibromin, like ~53, is a tumor suppressor gene prod- 
uct that is disrupted on the more general pathway 
to malignant transformation and neoplasia. Further 
work will be required to determine what role neurofi- 
bromin plays in the progression to the malignant 
state. 
Function(s) of Neurofibromin 
Three specific properties of neurofibromin have been 
suggested by recent studies: regulation of cellular 
proto-oncogenes (ras) important in growth and differ- 
entiative pathways; association with cytoplasmic micro- 
tubules; and involvement in phosphorylation-mediated 
signal transduction pathways. Neurofibromin, like its 
homologs in yeast and mammals, is a GAP and serves, 
at least in part, to accelerate the conversion of the active 
p21ras.GTPtotheinactivep21’~~.GDP(Figure4). In yeast, 
ras is involved in regulation of CAMP levels through 
adenylate cyclase. However,  in mammals its role is 
much less clear. 
In general, tumor suppressor genes that predispose Two models have been proposed for the interaction 
to familial cancer syndromes when inherited through between ras and GAP (McCormick, 1989): One model 
the germline are also capable of playing a role in spo- (the upstream model) envisions GAP acting as a regu- 
radic malignancy by somatic mutation. The same ap- lator of ras, accelerating the conversion of ras from 
pears to be trueof NF7. Examination of sporadic meta- theactivetothe inactive form through GTP hydrolysis. 
static malignant melanoma cell lines revealed the The second model (the downstream model) predicts 
absence of protein and/or mRNA in 2 of 9 cell lines that GAP functions as an effector for ras and that con- 
and a large homozygous deletion involving the amino- version of ras to the GDP-bound form transmits a sig- 
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nal through GAP to other proteins within the cyto- 
plasm. Neither of these models is mutually exclusive, 
and  it is equally possible that GAP and  ras transmit a  
signal only when complexed together. 
Ras has  been  shown to mediate differentiation in 
some tissue types (Schwann cells and  PC12 pheochro-  
mocytoma cells) and  proliferation in others (fibro- 
blasts) (Bar-Sag and  Feramisco, 1985;  Feramisco et al., 
1984;  Noda et al., 1985).  Regulat ion of this important 
cellular modulator is therefore critical for the mainte- 
nance  of the differentiated or proliferative state. To  
this end,  neurofibromin in its role as  a  tumor suppres-  
sor protein may keep the brake on  ras, and  its absence 
through mutation may result in disturbed growth or 
differentiative properties. Support  for this notion de-  
rives from the study of malignant neurof ibrosarcoma 
cells from patients with NFI (Basu et al., 1992;  DeClue 
et al., 1992).  In these cells, a  large proport ion of p21,as 
is in the active, CTP-bound form and  little or no  neu-  
rofibromin can be  detected. Given no  neurofibromin 
to down-regulate ras in these cells, ~21’~ remains ac- 
tive and  presumably contr ibutes to the abnormal  
growth characteristics of these cell lines. In addition, 
these neurof ibrosarcoma cells harbor  other chromo- 
somal aberrat ions that also may contribute to the phe-  
notype of these malignant cells. 
The  fact that ras is activated in these neurofibrosar- 
coma cell l ines which do  not express neurofibromin 
yet have  functional GAP molecules raises the ques-  
tion, what does  GAP actually have  to do  with ras regu- 
lation? The inability of GAP to down-regulate ras in 
these cells may be  explained in a  number  of ways: 
First, it is possible that GAP is actually a  target or ef- 
fector of ras function and  does  not down-regulate ras 
in vivo in Schwann cells. Second,  in Schwann cells, 
it may be  that neurofibromin, and  not GAP, is the 
predominant regulator of ras, and  al though both are 
present and  functional, only neurofibromin performs 
this function. Support  for this notion comes from ex- 
periments demonstrat ing the selective inhibition of 
GAP versus neurofibromin catalytic activity by  lipids. 
In Schwann cells, the predominant GAP activity is at- 
tributable to neurofibromin and  not GAP (Bollag and  
McCormick, 1991).  Lastly, a l though both are present 
and  functional, the ability to regulate ras depends  on  
the presence of other intracytoplasmic proteins, and  
the use of neurofibromin versus GAP as the primary 
ras regulator may depend  on  the availability of these 
proteins. To  this end,  in Schwann cells, the proteins 
that interact with GAP for adequate  GAP function may 
not be  available, and  neurofibromin is used preferen- 
tially. There are currently no  experimental data avail- 
able to support  this model.  
The  associat ion of neurofibromin with microtu- 
bules suggests additional roles for the NF7 gene  prod- 
uct. Neurofibromin could function as  a  regulator of 
raswhen released from microtubules, but may be  kept 
distant from p2l ,as by  virtue of its associat ion with 
the cytoskeleton when it is necessary that ras remain 
active. It is also possible that neurofibromin plays 
some specific role in the regulation of microtubule- 
mediated functions through its interaction with tu- 
bulin. 
Many  cellular proto-oncogenes are regulated 
through phosphorylat ion events initiating at the cell 
surface and  culminating in transcriptional regulation 
within the nucleus (Aaronson, 1991).  Mammalian GAP 
is tyrosine phosphory lated in response to growth fac- 
tor stimulation and  in this fashion may be  regulated 
either through its associat ion with a  distinct subset  of 
proteins (such as  c-mos, c-raf, or ERK proteins) or by  
down-regulat ion of its GTPase activating propert ies 
(Ellis et al., 1990;  Downward et al., 1990).  Neurofi- 
bromin is also phosphory lated in response to growth 
factors, but not on  tyrosine residues (Gutmann et al., 
1992,  Neurology, abstract). Instead, neurofibromin is 
heavily phosphory lated on  serine and  threonine resi- 
dues  in response to epidermal and  platelet-derived 
growth factors. This phosphorylat ion does  not result 
in alteration of its GAP activity, but it is conceivable 
that phosphorylat ion could change the intracellular 
localization of neurofibromin in relation to microtu- 
bules or its associat ion with other proteins. 
The Role of Neurofibromin in the Nervous System 
Role of Neurofibromin in Nervous 
System Development 
There is a  growing body  of ev idence to substantiate 
the claim that ras is important in the proper,  orderly 
development of the nervous system. In the best stud- 
ied system to date, the regulation of ras is critical to 
the development of the Drosophila compound eye 
(Fortini et al., 1992;  Pawson, 1990).  In this photorecep- 
tor system, several gene  products have  been  identi- 
fied that form a  cascade involving receptors with tyro- 
sine kinaseactivity(receptortyrosine kinases with the 
ability to phosphorylate proteins on  tyrosine resi- 
dues),  GTPase-act ivat ing proteins, and  ras. The  proper 
differentiation of one  of these photoreceptor cells (R7 
cell) requires an  inductive signal from a  neighbor ing 
photoreceptor cell (R8 cell) (Simon et al., 1991).  The  
R7 cell expresses a  receptor tyrosine kinase that is 
activated by  a  l igand expressed on  the surface of the 
R8 cell. Stimulation of the R7 receptor tyrosine kinase 
results in activation of Rasl and  proper differentiation 
of the R7 cell. A recently identified Drosophila GAP- 
like protein, Gapl, appears  to down-regulate Rasl and  
negatively regulates R7 determination (Gaul et al., 
1992).  The  orderly expression of the growth factor li- 
gand  and  its interaction with the R7 receptor tyrosine 
kinase constitute the upstream signaling components  
that regulate GAP and  ras in a  receptor-mediated sig- 
nal t ransduction pathway. Similar processes,  perhaps 
involving neurofibromin, may be  operat ive in the de-  
velopment of the mammalian nervous system. 
Review: Neurofibromatosis 
341 
Role of Neurofibromin in Neural 
Crest-Derived Tissues 
The expression of neurofibromin is presently be- 
ing investigated in two neural crest-derived tissues: 
Schwann cells and the pheochromocytoma cell line, 
PC12. In cultured Schwann cells, elevation of CAMP 
results in differentiation at least in part by up- 
regulation of growth factor receptor expression 
(Weinmaster and Lemke, 1990) and perhaps also 
through CAMP-dependent phosphorylation events in 
the cytoplasm or transcriptional events in the nucleus 
(Sobue et al., 1986). If ras is involved in the regulation 
of CAMP in mammalian cells, as it is in yeast, it is 
likely that the regulation of ras by neurofibromin may 
constitute a pathway important in modulating cell dif- 
ferentiation. In the PC12 model system, elevation of 
CAMP levels results in differentiation to a neuronal 
phenotype with sprouting of neuritic processes, simi- 
lar to the phenotype induced by nerve growth factor 
treatment (Richter-Landsberg and Jastorff, 1986). Like- 
wise, activation of ras by nerve growth factor stimula- 
tion or introduction of activated ras protein leads to 
PC12 cell differentiation (Bar-Sagi and Feramisco, 
1985). There is evidence to suggest the existence of at 
least two different pathways that culminate in PC12 
neurite extension: one pathway involves ras whereas 
the other is independent of ras and is mediated by 
CAMP (Colubeva et al., 1989; Miyasaka et al., 1991; 
Hagag et al., 1986; Hama et al., 1986; Sugimoto et al., 
1988). Further work will be required to determine 
whether these two seemingly independent pathways 
converge on a common protein modulator to culmi- 
nate in differentiation. 
Summary and Future Directions 
There are many more questions raised than answered 
by the cloning of the NH gene. Now that neurofi- 
bromin has been shown to be involved in the regula- 
tion of ras, to participate in protein kinase phosphory- 
lation cascades, and to be potentially associated with 
cytoplasmic microtubules, many new unexpected ar- 
eas for investigation are open: Studies aimed at better 
defining the role of neurofibromin in the regulation 
of ras will need to focus on determining the critical 
residues for neurofibromin-ras interaction, dissect- 
ing the mechanism for regulation of neurofibromin 
function, and deciding between the upstream and 
downstream models for neurofibromin-ras interac- 
tions. In this regard, further definition of the range of 
germline and somatic NF? mutations should assist in 
a better understanding of structure-function relation- 
ships, especially if more missense mutations can be 
found. Studies directed at understanding the role of 
neurofibromin in signal transduction cascades may 
shed some light on the potential sites for neurofi- 
bromin phosphorylation in response to growth fac- 
tors, the consequences of neurofibromin phosphory- 
lation, and determination of the intracellular protein 
targets for interaction with neurofibromin. An investi- 
gation of the association of neurofibromin with micro- 
tubules should elucidate the nature of this physical 
association, the elements required for regulation of 
this interaction, and the effects of up-regulating or 
down-regulating neurofibromin expression on micro- 
tubule-mediated functions. Lastly, the roleof neurofi- 
bromin in the nervous system may be better under- 
stood through an examination of its role in Schwann 
cell-mediated functions, neuronal regeneration, and 
Schwann cell and oligodendrocyte myelination. In- 
vestigations along these lines should provide poten- 
tially exciting insights into the multiple roles of neu- 
rofibromin within the nervous system. 
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